C12Y 207/11025
Mitogen-activated protein kinase kinase kinase , i.e. mapkkk or map3k
Official title: Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
C12Y207/11025 (Mitogen-activated protein kinase kinase kinase , i.e. mapkkk or map3k) appears on 19 US grants and 35 published applications in this corpus.
Search patents in C12Y- Granted patents
- 19
- Published applications
- 35
- Assignees
- 25
- Inventors
- 104
- Latest grant
- 22 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 4 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 0 | 3 |
| 2020 | 4 | 4 |
| 2021 | 3 | 4 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 3 | 4 |
| 2025 | 2 | 1 |
By publication year.
Recent patents
- Ganglioglioma-induced animal model and a method for diagnosing and treating ganglioglioma and related diseases22 Jul 2025US 12,364,776 B2Korea Advanced Institute of Science and Technology
- Dual leucine zipper kinase inhibitors for gene therapy8 Apr 2025US 12,270,033 B2Exhaura, Ltd.
- Inhibitors of SARM1 in combination with neuro-protective agents10 Sep 2024US 12,083,114 B2Disarm Therapeutics, Inc.
- MLK-regulated microRNAs in angiogenesis and tumor development10 Sep 2024US 12,083,143 B2University of Massachusetts
- Fusions and method for detecting same6 Aug 2024US 12,055,538 B2Japanese Foundation for Cancer Research
- Gene therapy for hearing loss6 Feb 2025US 2025/0041451 A1Perceive Biotherapeutics, Inc.
- MLK-Regulated microRNAs in Angiogenesis and Tumor Development5 Dec 2024US 2024/0398848 A1University of Massachusetts
- Gene therapy for neuroprotection4 Jul 2024US 2024/0216537 A1The Regents of the University of California
- Improved T cell receptor-costimulatory molecule chimera9 May 2024US 2024/0148869 A1
- Map kinase pathway targets for the treatment of marfan syndrome25 Jan 2024US 2024/0025982 A1The Johns Hopkins University
Most cited
By later US patents
- Antisense inhibition of MEKK2 expression114US 6,287,860 B1Isis Pharmaceuticals, Inc. · 2001
- BRAF-based polypeptides for treatment of cancer3US 11,338,012 B2University of the Sciences · 2022
- Engineered cell lines for increased protein production2US 10,577,613 B1Celltheon Corporation · 2020
- Fusions and method for detecting same2US 10,921,311 B2Japanese Foundation for Cancer Research · 2021
- Inhibitors of SARM1 in combination with neuro-protective agents2US 12,083,114 B2Disarm Therapeutics, Inc. · 2024